Manipal Health Enterprises debuted on NSE and BSE on August 5, 2026, listing at ₹652–655 — roughly 11% above its issue price of ₹590. The ₹9,275 crore IPO was priced at ~85–105x FY26 earnings, well above the listed hospital peer average, and raised ₹8,000 crore via a fresh issue — of which the bulk is earmarked for repaying subsidiary debt, not new hospitals.
India's largest private hospital network just went public at a valuation that made even its own analysts split: 6 said apply, 6 said avoid. The stock opened 11% above issue price. Markets cheered. But here is how a CFO reads this — and it starts with three words: use of proceeds.
Of the ₹9,275 crore raised, ₹8,000 crore is a fresh issue (new shares sold to the public, diluting existing holders). Of that, roughly ₹5,378 crore goes to repay debt at its hospital subsidiary. Another ₹574 crore buys out a minority stake in Sahyadri Hospitals. That is nearly 75% of fresh-issue capital going to clean up the balance sheet and consolidate ownership — not to build a single new bed.
A CFO would call this a balance-sheet IPO, not a growth IPO. The company is essentially asking public markets to refinance its debt at equity cost. That is fine — sometimes that is the right move — but it changes what you are really paying for at 100x earnings.
Valuation (Module 12) asks: what assumptions must hold for this price to make sense? At 105x P/E, you are not paying for today's profit. You are paying for a decade of compounding. If debt relief frees cash flows and beds scale, the math works. If hospital utilisation disappoints, 100x unwinds fast.
The listing pop felt like a win. A CFO reads the footnotes first.
📚 Learn the concept: Valuation
▶ Play the 90-second CFO game All daily posts